What is the recommended post‑exposure prophylaxis (PEP) for HIV in a male patient with possible exposure through receptive anal intercourse?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recommended HIV Post-Exposure Prophylaxis for Male Homosexual Patient

For a male patient with possible HIV exposure through receptive anal intercourse, initiate nonoccupational post-exposure prophylaxis (nPEP) immediately if presenting within 72 hours of exposure, using either bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a single-tablet regimen OR dolutegravir plus a tenofovir-based backbone (TAF or TDF) with emtricitabine or lamivudine for 28 days. 1

When to Initiate nPEP

nPEP is recommended when all of the following criteria are met 1:

  • Timing: Exposure occurred within the past 72 hours (ideally start within 24 hours)
  • Exposure type: Receptive anal intercourse without a condom represents substantial HIV transmission risk
  • Source status: The source person either:
    • Has confirmed HIV without sustained viral suppression, OR
    • Has unknown HIV status or unknown viral suppression status

Case-by-case determination is required when the source's HIV status is completely unknown 1.

nPEP is not recommended if the source has sustained viral suppression or is confirmed HIV-negative 1.

Preferred Medication Regimens

The 2025 CDC guidelines provide two preferred options for adults and adolescents 1:

Option 1: Single-Tablet Regimen

  • Bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (BIC/FTC/TAF)
  • One tablet daily for 28 days
  • Simplest option with lowest pill burden

Option 2: Multi-Component Regimen

  • Dolutegravir 50mg once daily
  • PLUS either tenofovir alafenamide (TAF) OR tenofovir disoproxil fumarate (TDF)
  • PLUS either emtricitabine (FTC) OR lamivudine (3TC)
  • Duration: 28 days

Regimen selection should account for 1:

  • Renal function (prefer TAF over TDF if creatinine clearance 30-60 mL/min)
  • Bone health concerns (prefer TAF if osteopenia/osteoporosis)
  • Drug interactions with current medications
  • Cost and access considerations
  • Tolerability and side effect profile

Critical Implementation Steps

Baseline Assessment

Before prescribing, complete 1:

  • HIV testing: Rapid point-of-care AND/OR laboratory-based antigen/antibody combination test
  • Do NOT delay first dose while awaiting lab results
  • Medical history including comorbidities, current medications, allergies
  • Assessment for acute HIV symptoms (fever, rash, lymphadenopathy)

Follow-Up Testing Schedule 1

  • 24 hours: Remote or in-person check-in with provider
  • 4-6 weeks post-exposure: Laboratory HIV Ag/Ab test PLUS diagnostic HIV NAT
    • May defer if nPEP started within 24 hours of exposure AND no doses missed
  • 12 weeks post-exposure: Final HIV Ag/Ab test PLUS diagnostic HIV NAT

Special Consideration: Long-Acting Injectable PrEP Exposure

If the patient received long-acting injectable cabotegravir PrEP within the past 12 months, add diagnostic HIV NAT at baseline in addition to standard Ag/Ab testing 1.

Transition to Pre-Exposure Prophylaxis (PrEP)

For patients with ongoing HIV exposure risk (common in MSM populations), plan immediate transition from nPEP to PrEP 1:

  • Complete HIV testing at end of 28-day nPEP course
  • If negative, transition directly to daily oral PrEP or long-acting injectable cabotegravir
  • This prevents gap in protection for high-risk individuals

Common Pitfalls to Avoid

  1. Delaying initiation: Every hour counts—start nPEP immediately, ideally within 24 hours. Do not wait for laboratory results 1.

  2. Missing the 72-hour window: While some experts argue for longer windows, evidence supports initiation only within 72 hours 1.

  3. Inadequate follow-up: Ensure adherence monitoring and completion of full 28-day course. Approximately 78% completion rates are reported in real-world settings 2.

  4. Failing to assess for PrEP transition: MSM seeking nPEP are at high ongoing risk—12% required repeat nPEP courses in one study 2. Proactive PrEP counseling is essential 3.

  5. Not considering source viral load: If the source has documented sustained viral suppression, nPEP may not be necessary 1.

Strength of Evidence

The 2025 CDC recommendations 1 represent the most current and authoritative guidance, though they acknowledge "very low certainty of evidence" for the specific preferred regimens. The recommendations are based on biological plausibility, safety profiles of newer antiretrovirals, and extrapolation from occupational PEP and PrEP efficacy data. Receptive anal intercourse represents one of the highest-risk exposures for HIV transmission, making nPEP particularly important in this population.

Expert consultation is available 24/7 through the National Clinician Consultation Center (PEPline) at 888-448-4911 for complex cases 1.

References

3
Research

Predictors of linkage to prevention services after HIV post-exposure prophylaxis (PEP): A single-centre retrospective analysis, years 2019-2024.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026

Related Questions

What is the recommended HIV post‑exposure prophylaxis regimen for a 17‑year‑old male who had unprotected receptive anal intercourse with a male partner last night, has never been tested for HIV, and does not know the partner’s HIV status?
What is the recommended post‑exposure prophylaxis (PEP) regimen for HIV after a needle‑prick injury, including the specific drugs, dosages, duration, and follow‑up HIV testing schedule?
What are the recommended post‑exposure prophylaxis (PEP) regimens for HIV, including dosing, renal‑function adjustments, pregnancy considerations, and alternative options?
What is the appropriate post‑exposure prophylaxis (PEP) regimen for a 27‑year‑old male who may have been exposed to HIV?
Is a negative rapid HIV finger‑prick antibody test performed 80 days after a possible exposure sufficient to rule out infection?
Can a urinalysis and urine culture be ordered simultaneously?
Does sertraline at doses of 150 mg and 200 mg have a clinically significant effect on dopamine?
Can Korlym (mifepristone) cause burning or stinging sensations in the legs and shortness of breath?
What are serum-sickness-like reactions and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome?
What preventive schedule is recommended for a patient with diagnosed Sjögren’s syndrome?
In a 64-year-old man who had a stroke two months ago and is on lisinopril 20 mg daily, valsartan 160 mg daily (restarted after fatigue), low‑dose aspirin 81 mg daily, atorvastatin 40 mg daily, folic acid 1 mg daily, and has not been taking his metoprolol, what is the appropriate management for secondary stroke prevention and blood‑pressure control?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.